Cure Pharmaceuticals Announces Positive Results from Study at Cincinnati Children's Hospital Medical Center (CCHMC) using Cure's Proprietary Single High-Dose Vitamin D (OTF) in Pediatric Patients Before and After Hematopoietic Stem Cell Transplantation (HSCT) |  MarketScreener

Cure Pharmaceuticals Announces Positive Results from Study at Cincinnati Children’s Hospital Medical Center (CCHMC) using Cure’s Proprietary Single High-Dose Vitamin D (OTF) in Pediatric Patients Before and After Hematopoietic Stem Cell Transplantation (HSCT) | MarketScreener

  • CURE’s patented and patented Vitamin D OTF has been found to be more effective than standard supplementation in achieving adequacy of pre- and postoperative vitamin D necessary to reduce immune-induced damage such as graft-versus-host disease (GVHD)
  • CCHMC Seeks Prescribing Approval for CURE’s OTF Vitamin D Supplement in Her Hospital Formulary

OXNARD, CA, May 12, 2022 (GLOBE NEWSWIRE) — CURE Pharmaceutical Holdings (OTC: CURR), a developer and manufacturer of innovative delivery formulations for drugs, supplements, and wellness products, today announced positive results from a study conducted in Cincinnati using Children’s Hospital Medical Center (CCHMC). ) of Cure, Single Dose, Oral, 40,000 IU of Vitamin D (Brand ImmunD3™ Nutri-Strips™ in Health Care Retail Market) in pediatric patients prior to stem cell therapy. CURE’s oral vitamin D supplement has been found to be more effective than standard supplementation in achieving pre- and postoperative vitamin D adequacy, which is critical for reducing immune-mediated organ damage in children receiving HSCT.

To view details of this study, visit the poster presentation on the CURE website at https://curepharmhemical.com/white-papers/

“The results for our oral vitamin D film, which we call ImmunD3 NutriStrips, are so remarkable for its ability to improve bone health and reduce complications in pediatric patients, and it also brings additional hope to parents and their children undergoing stem-HSCT,” said Rob Davidson. Cure Pharmaceutical CEO, “Cellular Therapy for Life-Threatening Diseases.” “If we could reduce the risk of complications by raising these children to optimal vitamin D levels before surgery, and in the acute period after transplant, we would have helped reduce pain and suffering. and save lives.”

Next Steps: Adding CURE Oral Vitamin D to Formulas Nationwide
Since previous attempts to improve vitamin D deficiency in these young patients who use additional doses and/or higher doses of enteral vitamin D are often unsuccessful, CCHMC is working with its formulary to add CURE’s NutriStrip Vitamin D formula to the list of treatments. approved.

Davidson added: “We are also pleased that the CCHMC team found these results so compelling to begin the process of including what we call ‘ImmunD3 Nutri-Strips™’ in their hospital prescription booklet. In light of this progress, we plan to reach out to other children’s hospitals across the United States from in order to share these compelling results and to strive to add our own Vitamin D into their formulations.”

The use of CURE’s delivery technology is important because it overcomes many barriers to adequate replacement with conventional vitamin D. Some of these drawbacks include:

  • Secondary malabsorption of GVHD
  • Inability to take capsules
  • mucosal inflammation
  • Kidney disease
  • Liver disease
  • infection

More about studying
The CCHMC study found that compliance and tolerance also improved, with patients and parents expressing a preference for the strips. The median age of the study group was 8 years, with a range of 1 to 28 years, and doses varied widely, from 1 strip per month to 4 strips per week, and all patients showed improvement in their serum vitamin D levels by Week 4 in the study. Mean baseline vitamin D level was 29.4 ng/ml, significantly improved (mean baseline vitamin D level was 29.4 ng/ml, and significantly improved (p 0.0001) to 5.5 ng/ml at end the study).

About Vitamin D and Pediatric Hematopoietic Stem Cell Transplant Patients
Vitamin D is essential for bone health and has immunomodulatory properties. Most pediatric patients are vitamin D deficient (<30 ng/ml) prior to HSCT. Standard supplementation strategies fail to achieve vitamin D adequacy in the acute post-transplant period, and there are scant data to support optimal vitamin D supplementation in these patients. This study, whose poster can be found here: https://curepharm Pharmaceutical.com/white-papers/, sought to assess whether very high-dose, weight-dependent oral vitamin D was more effective than standard supplements in Achieving vitamin D sufficiency before HSCT and reducing the incidence of HSCT-related complications (graft-versus-host disease, veno-occlusive disease, and/or transplant-related thrombotic microangiopathy) associated with immune endothelial damage. Secondary endpoints examined the immune-modifying properties of vitamin D.

About Cure Pharmaceuticals
Cure Pharmaceuticals® is the leading developer of CUREform™, a patented drug delivery platform that delivers a number of unique, controlled drug delivery compounds that are designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. Among CURE’s main products is their oral thin film, which contains 40,000 IU of Vitamin D (brand Nutri-Strips™ in retail). Each tape is airtight in an airtight package to eliminate chemical and structural breakdown and provide superior strength. Nutri-Strips™ is available online at https://www.nutristripnow.com/immund3

As a vertically integrated company, CURE’s 25,000 square feet, registered with the FDA, NSF® And its cGMP certified manufacturing facility enables it to partner with pharmaceutical and wellness companies around the world for private and white label production. CURE has partnerships in the United States, China, Mexico, Canada, Israel and other markets in Europe.

forward-looking statements
Statements made by CURE in this press release may include statements that are not historical facts and are forward-looking within the meaning of Section 27A of the Securities Exchange Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. modified (“law of exchange”), which is usually identified using words such as “expects,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” and seeks,” “should,” “will,” and various forms of these words or similar expressions. CURE intends that these forward-looking statements are covered by the safe harbor provisions of the forward-looking statements in Section 27A of the Securities Exchange Act and Section 21E of the Stock Exchange and makes this statement for purposes of complying with the Safe Harbor Terms. The forward-looking statements contained in this press release reflect Cure’s judgment as of the date of this press release. CURE disclaims any intention or obligation to update these forward-looking statements.

Contacts:

Investor Relations
Investor@curepharma.com
(805) 410-9962 ext. 4

2022-05-12 17:43:02

Leave a Comment

Your email address will not be published. Required fields are marked *